Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is bimatoprost grenod (NCX 470), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox SA generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the United States, and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	32.65M 37.36M 30.13M 27.77M 52.35M 3.6B 53.51M 360M 142M 1.76B 140M 137M 6.07B	P/E 2026 *	-5.29x	P/E 2027 *	37.1x
Enterprise Value	32.65M 37.36M 30.13M 27.77M 52.35M 3.6B 53.51M 360M 142M 1.76B 140M 137M 6.07B	EV / Sales 2026 *	10.9x	EV / Sales 2027 *	3.27x
Free-Float	99.65%	Yield 2026 *	-	Yield 2027 *	-

07-01	Nicox Submits NCX 470 New Drug Application In The United States	CI
07-01	Nicox files U.S. marketing approval application
06-23	Nicox Bags EUR6 Million Shareholder Loan	MT
06-23	Nicox Secures Backing From a Shareholder and Financial Partner
06-18	Nicox Receives Positive Feedback from China
06-18	Nicox Announces Positive Pre-Submission Regulatory Feedback in China Supporting NDA Filing for NCX 470	CI
04-29	Nicox S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-24	Nicox SA Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting	CI
02-24	Edenred, Forvia, Freelance.com... Key Stocks to Watch Today in Paris -
02-24	Nicox Reports Positive Phase 3 Results for NCX 470
02-16	Nicox, Sanofi, Valneva... Stocks to Watch Today in Paris
02-16	Nicox Moves Forward with U.S. Health Authorities for Its NCX 470
01-05	Nicox Strengthens Its Financial Position

07-01	Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment	GL
06-23	Nicox and Vester Finance Sign Shareholder Loan Agreement to Support Strategic Activities for the Company	GL
06-18	Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470	GL
06-08	Reminder: Nicox June 2024 Warrants will expire June 19, 2026	GL
06-03	Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 24, 2026 and appointment of an ad hoc representative	GL

07-01	Bourse : Schneider se renforce dans l'IA, Air Liquide investit pour SK Hynix, Nike déçoit
07-01	Nicox dépose une demande d'autorisation de mise sur le marché aux Etats-Unis
07-01	La Bourse s'habitue à tout
07-01	Nicox : Demande d’autorisation de mise sur le marché de NCX 470 soumise aux Etats-Unis par Kowa, avec un paiement d’étape de 3 millions d’euros associé
06-23	Bourse : Sanofi enchaîne les AMM, Prysmian enchaîne les contrats, l'IA enchaîne les dépenses

Manager	Title	Age	Since
Gavin Spencer CEO	Chief Executive Officer	55	2024-02-27
Sandrine Gestin DFI	Director of Finance/CFO	58	2014-12-31
Doug Hubatsch CTO	Chief Tech/Sci/R&D Officer	-	2021-12-12

NicOx SA Stock Euronext Paris

Stocks

NCOX

FR0000074130

Pharmaceuticals

Valuation: NicOx SA

Latest news : NicOx SA

Press Releases: NicOx SA

News in other languages: NicOx SA

Quotes and Performance

Managers and Directors: NicOx SA

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Director	Title	Age	Since
Gavin Spencer BRD	Director/Board Member	55	2024-04-07
Damian Marron CHM	Chairman	64	2024-07-15
Marc Bozec BRD	Director/Board Member	-	2024-07-15

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NICOX SA	-7.95%	-9.39%	-	-	37.36M
MERCK & CO., INC.	-0.10%	+3.21%	+56.40%	+20.77%	315B
MERCK KGAA	-1.20%	-2.43%	+22.19%	-8.40%	67.81B
HALOZYME THERAPEUTICS, INC.	+0.35%	+2.11%	+34.61%	+93.22%	9.23B
KYOWA KIRIN CO., LTD.	+0.34%	+0.51%	+4.67%	+0.09%	8.56B
SK BIOPHARMACEUTICALS CO., LTD.	+1.53%	-3.64%	-22.99%	+3.93%	4.18B
BETTA PHARMACEUTICALS CO., LTD.	-11.03%	-12.07%	-5.25%	+15.98%	3.59B
YUHAN CORPORATION	+1.87%	+3.36%	-47.86%	+27.51%	3.55B
SUPERNUS PHARMACEUTICALS, INC.	-0.35%	-0.87%	+43.02%	+63.23%	2.79B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-7.41%	-2.37%	+3.82%	-22.47%	2.09B
Average	-2.40%	-1.72%	+9.84%	+21.54%	46.3B
Weighted average by Cap.	-0.36%	+1.02%	+46.72%	+17.12%

	2026 *	2027 *
Net sales	3M 3.43M 2.77M 2.55M 4.81M 331M 4.92M 33.09M 13.01M 162M 12.89M 12.61M 557M	10M 11.44M 9.23M 8.51M 16.03M 1.1B 16.39M 110M 43.38M 540M 42.97M 42.03M 1.86B
Net income	-6M -6.87M -5.54M -5.1M -9.62M -661M -9.83M -66.18M -26.03M -324M -25.78M -25.22M -1.11B	1M 1.14M 923K 851K 1.6M 110M 1.64M 11.03M 4.34M 53.97M 4.3M 4.2M 186M
Net Debt	-	-